CNGB Virogin’s VG161 On Track for Breakthrough Designation in China for Advanced Liver Cancer
BEIJING—CNGB Virogin, a joint venture between Virogin Biotech and China National Biotec Group, is poised...
China’s Healthcare Statistics Show Improvements in Life Expectancy and Access to Medical Services
BEIJING—The National Health Commission (NHC) of China has published the “China’s Healthcare Statistical Communique 2023,”...
Mindray Bio-Medical Electronics Reports 11.12% YOY Revenue Growth in 2024H1
SHENZHEN—Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760) has announced its financial results for the first...
Hua Medicine’s 2024H1 Revenues Surge on HuaTangNing Sales; Path to Profitability in Sight
HONG KONG—Hua Medicine (HKG: 2552), a China-based pharmaceutical company, has announced its financial results for...
American Government Funds Bolster Chinese Inventors’ Patents, According to USPTO Data
WASHINGTON—A Reuters investigation into the United States Patent and Trademark Office (USPTO) data has uncovered...
GeneQuantum Appoints Dr. Lingyu Zhu as Chief Business Strategy and Development Officer
SUZHOU—GeneQuantum, a leading player in the biotech industry known for its cutting-edge enzymatic site-specific conjugation...
Jiangxi Healthcare Security Administration Launches Initiative to Widen Drug Availability
JIANGXI—In a strategic move to enhance drug accessibility, the Healthcare Security Administration (HSA) bureau of...
China’s Supreme Court Deals Blow to Sanofi’s Aubagio, Confirms Patent Cancellation
BEIJING—In a recent development for the pharmaceutical industry, Sanofi’s multiple sclerosis therapy Aubagio (teriflunomide) has...
Pfizer Partners with Quotient Therapeutics for Somatic Mutations Research in Cardiovascular and Renal Diseases
NEW YORK—Pfizer Inc., a pharmaceutical giant listed on the New York Stock Exchange (NYSE: PFE),...
Sackler-Owned Mundipharma Fails to Secure $1 Billion Valuation for China Unit
LONDON—Mundipharma International Ltd., the UK-based pharmaceutical firm with ties to the Sackler family of the...
Sinopharm and Ruidio Pharmaceutical Advance in Priority Review for Innovative Drugs and Vaccines
BEIJING—The Center for Drug Evaluation (CDE) has indicated that two Chinese companies, Foshan Ruidio Pharmaceutical...
Jiangsu Simcere and AnDiConBio’s Anti-Influenza Drug ADC189 Doses First Patient in Phase III Study
JIANGSU—In a significant development for the pharmaceutical industry, Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096),...
Sino Biopharmaceutical’s Anlotinib-Penpulimab Combo Meets Milestone in Phase III HCC Study
HONG KONG—Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced...
Leaderna Therapeutics Secures RMB 100 Million in Funding to Accelerate Nucleic Acid Drug Development
CHENGDU—Leaderna Therapeutics Ltd, a pioneering nucleic acid drug developer, has reportedly secured nearly RMB 100...
Advancing Peripheral Artery Disease Care: Boston Scientific’s JETSTREAM Receives Marketing Nod in China
NEW YORK—Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical solutions, has secured a...
China’s New Medical Device Regulations: A Comprehensive Framework for Industry Growth and Safety
BEIJING—China’s National Medical Products Administration (NMPA) has unveiled a draft proposal for the “Medical Device...
Innovent Biologics Reports 46.3% YOY Revenue Growth and Expands Portfolio with New Approvals and NDAs
Innovent Biologics, Inc., a leading biopharmaceutical company based in China and listed on the Hong...
Tigermed Partners with Beijing Government to Open North Headquarters, Expanding Collaboration in Biotech
Tigermed, a prominent Contract Research Organization (CRO) with a presence in both Shenzhen (SHE: 300347)...
Luye Pharma Group’s 2024H1 Revenue and Net Profits Surge, Driven by Oncology and CNS Therapy Revenues
Luye Pharma Group, a China-based pharmaceutical company listed in Hong Kong (HKG: 2186), has reported...
Asieris Pharmaceuticals Reports Explosive 103,397.96% YOY Revenue Growth in 2024H1 Financial Report
Asieris Pharmaceuticals, a China-based urogenital cancer specialist listed on the Shanghai Stock Exchange (SHA: 688176),...